A new treatment option that is basically depressing the body’s hormone producing agents, and for use with advanced stages of the disease.
“Degarelix was at least as effective as leuprolide in achieving and maintaining castrate levels of testosterone.”
There are side effects such as hot flushes, increased weight, and fatigue since the drug is suppressing hormone generation of the body and the product is an injection, not a tablet or pill so the injection site could also be an area of concern as far as irritation. The product is to become available very soon in the US and other markets are pending. BD
Ferring Pharmaceuticals, USA today received approval from the U.S. Food and Drug Administration (FDA) for degarelix, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist, indicated for patients with advanced prostate cancer. Potential trade names are still under review with the FDA. Following issuance of a trade name, Ferring Pharmaceuticals, USA will immediately begin commercialization in the U.S. On December 18, the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMEA), recommended granting a marketing authorization for degarelix in Europe. Degarelix is awaiting approval in other key global markets. It is a milestone for the company and represents Ferring's first global product launch.